News

Supported by a £4.7million award from Department of Health and Social Care, managed by Innovate UK, the project aims to take two new vaccine candidates through to a

Sangamo’s platform will be used to develop next-generation ex vivo cell therapies in oncology. Under the worldwide collaboration, Kite will get exclusive rights to use the ZFN technology to modify

The partnership will use Emulate’s Human Emulation System across R&D programs to allow more human-relevant studies that will result in earlier and better prediction of safety and efficacy of

ATUM CEO Dr Jeremy Minshull said: “We love everything about Just’s mission, and we are delighted that our Leap-In technology will be used to help democratize access to

INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. Under the Prescription Drug User Fee Act

The transaction, which will be carried out by a subsidiary of Merck, will expand the company’s immuno-oncology pipeline with the addition of Viralytics’ Cavatak (CVA21), an investigational oncolytic

Under the terms of the agreement, Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million

The objective of this Phase 1 is to determine safety, bio-distribution, and preliminary effectiveness of AlphaMedix in patients with somatostatin receptor positive neuroendocrine tumors (NETs). Orano Med’s CEO

The approval of the company’s New Drug Application (NDA) was granted under the US President's Emergency Plan for AIDS Relief (PEPFAR). Following the approval, Mylan said that it